Summer Meeting App
Download the meeting app for Apple or Android devices using the buttons below:
Photos from BAP 2016 Summer Meeting in Brighton. Great science, networking, and all with sun at the seaside!
The BAP is a learned society and registered charity. It promotes research and education in psychopharmacology and related areas, and brings together people in academia, health services, and industry. Formed in 1974, it is the largest such national association in Europe, and the second largest in the world.
Read more about BAP
Apply for membership
Benefits of BAP membership include:
- FREE subscription and access to the Journal of Psychopharmacology (published monthly online).
- Reduced registration fees for the annual Summer Meeting.
- Half price subscription to the Online CPD Resource.
- Eligibility for prizes and awards.
- Student bursaries for the BAP Summer Meeting and international conferences.
- Reduced registration fees for selected partner association events.
- 50% OFF Royal Society of Biology membership (Read more)
- BAP Newsletter.
- Voting for BAP Officers and Council (full members only).
- Being part of one of the largest national psychopharmacology associations in the world.
New world order: Brexit, drugs and research
Whether you voted remain or leave, the vote to leave the EU ('Brexit') is going to have a major impact for our field and drug regulation. It will affect our ability to attract the best talent from the rest of Europe, our capacity to collaborate internationally, and to access EU science funding. It will also affect the regulation of drugs, much of which is performed at a European level. Moreover, it is inevitable that the European Medicines Agency (EMA) will move from the UK. This may have knock-on effects for psychopharmacology as some companies will probably relocate their European headquarters to be near the EMA.
We have an opportunity now to influence the UK Government to ensure the post-Brexit world is the best it can be for the field. With this in mind I recently wrote to the House of Commons Science and Technology Committee to raise some of these issues on behalf of the BAP. Please see my letter below. I urge BAP members to take action individually and through their universities and other fora.
BAP letter to Nicola Blackwood, Chair of the House of Commons Science and Technology Committee
Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology
A few years ago on the Journal of Psychopharmacology I published an editorial on the need for a new nomenclature in
psychopharmacology [Nutt DJ. (2009) Beyond psychoanaleptics - can we improve antidepressant drug nomenclature?
J Psychopharmacol. 23(4):343-5. Erratum in: J Psychopharmacol. 23(7):861].
This sparked interest from the ECNP who set up a working group with several other international psychopharmacology
organisations e.g. ACNP CINP, and after 5 years of regular meetings a new nomenclature has been develop and posted as a
free educational App.
The next stage is to begin the challenging process of using the new nomenclature in scientific journals and the
Journal of Psychopharmacology is one of about 10 who have agreed to try to do this. The details are in an editorial
in the next edition of the Journal.
So when you write your papers for Journal of Psychopharmacology or Therapeutic Advances in Psychopharmacology please try to
use the attached glossary to explain what drugs you use are and how they work.
Fundamentals of Clinical Psychopharmacology Fourth Edition Out Now
The new edition of the BAP book, Fundamentals of Clinical Psychopharmacology, published in August 2015, is available for purchase here for £20 (RRP £29.99), including postage and packaging.
Fundamentals of Clinical Psychopharmacology provides up-to-date, evidence-based and unbiased information about psychopharmacology. It spans the range of the discipline, from mode of action and side effects of drugs to meta-analyses of clinical trials. It is anchored to practice guidelines produced by the UK National Institute for Health and Care Excellence (NICE) and the British Association for Psychopharmacology (BAP). Care has been taken to provide an international perspective that makes it equally useful to practitioners in the US and other countries. Read more on the publishers website.
Buy the book
The Ten Secrets of Success in Science by Professor Trevor Robbins
The BAP takes supporting the next generation of clinical and preclinical scientists seriously. We do this in a number of ways, including offering discounted trainee membership, support to attend our meetings, training in clinical and non-clinical psychopharmacology, and generous prizes and bursaries to recognise the work of trainees and support them to attend our meetings and other conferences.
We also run a dedicated Trainees' Workshop at our annual meeting to help students and early career researchers develop their careers. Topics have included how to get started in research, how to combine research with family life, how to develop a career in clinical and/or preclinical research and working in industry.
This year in Bristol the workshop included an interactive discussion on the secrets of success in science from Professor Trevor Robbins. Professor Robbins is arguably one of the top ten neuroscientists in the World and has had a major impact on the field. He has also supervised and mentored over 80 PhD and post-doctoral researchers, many of whom have gone on to head research teams in their own right.
You can hear Professor Robbins summarising his top ten secrets for success based on the workshop at this year's summer meeting in the video (above). There are some interesting surprises and there was much more that came out at the workshop!
BAP will run another Trainees' Workshop at the next summer meeting in Brighton, 17-20 July 2016.
BAP endorses the Fact Sheet on Ketamine Scheduling
Fact Sheet on Ketamine Scheduling (updated 27 Feb 2015)
Extended Fact Sheet on Ketamine Scheduling
Members of CND
International Federation of Red Cross and Red Crescent (IFRC) position paper
Schedule II and IV requirements
Essential veterinary use of ketamine
Read Professor David Nutt's article on the ketamine ban
Update 24 February – in response to a letter from BAP, the Chief Medical Officer, Professor Dame Sally Davies, replies “I would like to assure you that the UK Government supports the continued medical and scientific use of ketamine for the reasons that you have set out. The UK Government will make this point in international fora as appropriate, and will not support its scheduling under the international drug conventions.”
Update 27 February – the final version of the fact sheet and additional advocacy documents are now available to download (above).
Where is the BAP Stand?
Below is a list of events where the BAP stand will be:
Cambridge TV - Sex Differences
Julia talked to Cambridge TV about how studies on sex differences are often over simplified and taken out of context by journalists. Read Article
1st June 2016
David Nutt, Robin Carhart-Harris and Phil Cowen
Magic mushrooms 'promising' in depression
David, Robin and Phil talk to the BBC about recent research into psilocybin, the hallucinogenic chemical in magic mushrooms.
17th May 2016
Mental Health Awareness Week: 'healthy relationships vital to well-being'
Andrew hosted an event at Bournemouth Station with Dorset Mind, the Samaritans, Richmond Fellowship and Time to Change, as part of Mental Health Awareness Week
16th May 2016
See more Members' Activities